These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32053030)

  • 1. Toxicological profile of lipid-based nanostructures: are they considered as completely safe nanocarriers?
    Azarnezhad A; Samadian H; Jaymand M; Sobhani M; Ahmadi A
    Crit Rev Toxicol; 2020 Feb; 50(2):148-176. PubMed ID: 32053030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of physicochemical properties on biological effects of lipid nanoparticles: Are they completely safe.
    Yuan Z; Yan R; Fu Z; Wu T; Ren C
    Sci Total Environ; 2024 Jun; 927():172240. PubMed ID: 38582114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid nanocarriers: influence of lipids on product development and pharmacokinetics.
    Pathak K; Keshri L; Shah M
    Crit Rev Ther Drug Carrier Syst; 2011; 28(4):357-93. PubMed ID: 21967401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomaterials meet zebrafish: Toxicity evaluation and drug delivery applications.
    Jia HR; Zhu YX; Duan QY; Chen Z; Wu FG
    J Control Release; 2019 Oct; 311-312():301-318. PubMed ID: 31446084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-nucleic acid nanoparticles of novel ionizable lipids for systemic BMP-9 gene delivery to bone-marrow mesenchymal stem cells for osteoinduction.
    Vhora I; Lalani R; Bhatt P; Patil S; Misra A
    Int J Pharm; 2019 May; 563():324-336. PubMed ID: 30954673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification Strategies of Lipid-Based Nanocarriers for Mucosal Drug Delivery.
    Wu L; Liu M; Zhu X; Shan W; Huang Y
    Curr Pharm Des; 2015; 21(36):5198-211. PubMed ID: 26412355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solid lipid nanocarriers in drug delivery: characterization and design.
    Mu H; Holm R
    Expert Opin Drug Deliv; 2018 Aug; 15(8):771-785. PubMed ID: 30064267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health hazards associated with nanomaterials.
    Pattan G; Kaul G
    Toxicol Ind Health; 2014 Jul; 30(6):499-519. PubMed ID: 23012342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicological Concerns of Engineered Nanosize Drug Delivery Systems.
    Mukherjee B; Maji R; Roychowdhury S; Ghosh S
    Am J Ther; 2016; 23(1):e139-50. PubMed ID: 24100254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery.
    Battaglia L; Gallarate M
    Expert Opin Drug Deliv; 2012 May; 9(5):497-508. PubMed ID: 22439808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of microbial biofilms - the contribution of micro and nanostructured materials.
    Grumezescu AM; Chifiriuc CM
    Curr Med Chem; 2014; 21(29):3311. PubMed ID: 24606506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicine-nanoscale drugs and delivery systems.
    Singh S
    J Nanosci Nanotechnol; 2010 Dec; 10(12):7906-18. PubMed ID: 21121278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing cellular toxicities in fibroblasts upon exposure to lipid-based nanoparticles: a high content analysis approach.
    Solmesky LJ; Shuman M; Goldsmith M; Weil M; Peer D
    Nanotechnology; 2011 Dec; 22(49):494016. PubMed ID: 22101838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in the Design and Evaluation of Polymeric Nanocarriers: The In Vitro Nano-Bio Interactions.
    Bettencourt A; Gonçalves LM
    Adv Exp Med Biol; 2022; 1357():19-41. PubMed ID: 35583639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics.
    Gindy ME; Feuston B; Glass A; Arrington L; Haas RM; Schariter J; Stirdivant SM
    Mol Pharm; 2014 Nov; 11(11):4143-53. PubMed ID: 25317715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery.
    Cheng X; Lee RJ
    Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):129-137. PubMed ID: 26900977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biohybrid Nanoparticle-Based In Situ Monitoring of In Vivo Drug Delivery.
    Ju S; Cho HY
    Biosensors (Basel); 2023 Dec; 13(12):. PubMed ID: 38131776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus.
    Sato Y; Matsui H; Yamamoto N; Sato R; Munakata T; Kohara M; Harashima H
    J Control Release; 2017 Nov; 266():216-225. PubMed ID: 28986168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyaluronan-Inorganic Nanohybrid Materials for Biomedical Applications.
    Cai Z; Zhang H; Wei Y; Cong F
    Biomacromolecules; 2017 Jun; 18(6):1677-1696. PubMed ID: 28485601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein-lipid nanohybrids as emerging platforms for drug and gene delivery: Challenges and outcomes.
    Gaber M; Medhat W; Hany M; Saher N; Fang JY; Elzoghby A
    J Control Release; 2017 May; 254():75-91. PubMed ID: 28365294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.